Showing 1761-1770 of 2105 results for "".
- Zavzpret Now Available in US Pharmacies as a Nasal Spray Treatment for Migrainehttps://practicalneurology.com/news/zavzpret-now-available-in-us-pharmacies-as-a-nasal-spray-treatment-for-migraine/2470250/Zavzpret (zavegepant; Pfizer, New York, NY), a nasal spray that treats migraine, is now available in US pharmacies as a package of 6 single-use, disposable devices that deliver a 10 mg dose. The
- CGRP mAbs Are Effective Long-Term for Migraine Prevention According to 3-Year Longitudinal Studyhttps://practicalneurology.com/news/cgrp-mabs-are-effective-long-term-for-migraine-prevention-according-to-3-year-longitudinal-study/2470218/Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) demonstrated long-term efficacy in preventing migraines, according to a study presented at the 65th Annual Scientific Meeting of the American Head
- Five-Year Data from ALITHIOS Study on MS Disability Presented at AAN 2023https://practicalneurology.com/news/five-year-data-from-alithios-study-on-ms-disability-presented-at-aan-2023/2470163/According to long-term results of a study presented at the Americ
- Combination Therapy May Reduce Weight Gain in Young Adults With Serious Mental Illnesshttps://practicalneurology.com/news/combination-therapy-may-reduce-weight-gain-in-young-adults-with-serious-mental-illness/2470145/Accord
- Open Label Extension Trial of Ozanimod Confirms Disease Stability at 6-7 Yearshttps://practicalneurology.com/news/open-label-extension-trial-of-ozanimod-confirms-disease-stability-at-6-7-years/2470126/Data from 2 phase 3 trials and one open label extension study (OLE) used to evaluate long-term efficacy by patient age group were presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRI
- Brand-Name Epilepsy Drug Costs Increase Almost Threefold Over 8 Yearshttps://practicalneurology.com/news/brand-name-epilepsy-drug-costs-increase-almost-threefold-over-8-years/2469944/According study published in Neurology, there was threefold increase in the cost of brand-name antiseizure medications (ASMs) in from 2010 to 2018. Brand-name medications comprised 79% of ASM costs although they made up only 14% of ASMs used. “The costs for brand-name A
- Rimegepant Dual Treatment Efficacy and Safety Maintained Over a Year of Treatmenthttps://practicalneurology.com/news/rimegepant-dual-treatment-efficacy-and-safety-maintained-over-a-year-of-treatment/2469936/In an open-label extension study (NCT03732638), adults (n-603) treatment with 75 mg of rimegepant (Nurtec; Biohaven, New Haven, CT) every other day, with the option of additional doses as acute treatment on the other days, had reduced
- Aducanumab Treatment for 2 Years or More Decreases Amyloid Beta and Phosphorylated Tau 181 Correlating With Reduced Cognitive Declinehttps://practicalneurology.com/news/aducanumab-treatment-for-2-years-or-more-decreases-amyloid-beta-and-phosphorylated-tau-181-correlating-with-reduced-cognitive-decline/2469853/New data show continued reductions in amyloid β (Aβ) plaques and plasma levels of phosphorylated tau 181 (ptau-181) after 128 weeks of treatment with aducanumab (Aduhelm; Biogen, Cambridge, MA). Participants with greater decreases in Aβ were more likely to have decreased in p-tau18
- Global Ischemic Stroke Mortality Rate Lowered Over Last 30 yearshttps://practicalneurology.com/news/global-ischemic-stroke-mortality-rate-lowered-over-last-30-years/2469782/As published in Neurology, the mortality rates for stroke decreased slightly from 1990 to 2019 worldwide. However, the number of individuals who died is still high, specifically in high- and middl
- Blood Test May Accurately Predict Progression to Alzheimer Disease 6 Years Before Diagnosishttps://practicalneurology.com/news/blood-test-may-accurately-predict-progression-to-alzheimer-disease-6-years-before-diagnosis/2469675/In a retrospective longitudinal study, available as a preprint prior to peer review, a prognostic blood biomarker test (AlzoSure Predict; Diadem, Milan, Italy) identified people who progressed from normal cognition or mild cognitive impairment (MCI) to Alzheimer disease (AD). The study used a con